1. | EXECUTIVE SUMMARY |
1.1. | Scope of the report |
1.2. | Benefits of electronic skin patches as a form factor |
1.3. | Market push and pull drivers |
1.4. | Skin patch applications overview |
1.5. | Diabetes management devices: electronic skin patches increase patient comfort |
1.6. | Diabetes management device roadmap: Glucose sensors |
1.7. | Key points for diabetes management devices: continuous glucose monitoring |
1.8. | Diabetes management device roadmap: Insulin delivery |
1.9. | Key points for diabetes management devices: insulin delivery |
1.10. | Atrial fibrillation: electronic skin patches addresses key industry pain points |
1.11. | Diagnosis process for atrial fibrillation and other arrhythmias |
1.12. | Key points for cardiac monitoring: Holter, mobile cardiac telemetry & event monitor |
1.13. | Vital sign monitoring: electronic skin patches increase patient mobility |
1.14. | Emerging application: Decentralized clinical trials |
1.15. | Key points for general vital sign monitoring |
1.16. | Other applications: temperature, electrical stimulation, iontophoresis and sweat sensing |
1.17. | Electronic skin patch manufacturing process |
1.18. | Material requirements for an electronic skin patch |
1.19. | Electronic skin patches global market annual revenue historic data and forecast 2010-2033 |
1.20. | Electronic skin patches global market annual revenue forecast 2022-2033 |
2. | INTRODUCTION |
2.1. | How to use this report |
2.2. | Definitions |
2.3. | The case for skin patches: augmenting the human body |
2.4. | Electronic skin patches within wearable technology progress |
2.5. | Benefits of electronic skin patches as a form factor |
2.6. | Market push and pull drivers |
2.7. | Key milestones in the history of skin patches |
2.8. | COVID-19 effect on electronic skin patches |
2.9. | Privacy and IT challenges |
2.10. | Reimbursement drives commercial business models |
2.11. | Reimbursement codes (US) |
2.12. | Skin patch applications overview |
2.13. | Skin patch applications overview |
2.14. | Skin patch applications overview |
3. | DIABETES MANAGEMENT VIA SKIN PATCHES |
3.1.1. | Background: Introduction to diabetes |
3.1.2. | The prevalence of diabetes |
3.1.3. | Diabetes management ecosystem |
3.1.4. | Background: Diabetes on the rise |
3.1.5. | Diabetes management device roadmap: Summary |
3.1.6. | Electronic skin patches in diabetes management: company profiles |
3.2. | Continuous glucose monitoring |
3.2.1. | Diabetes management device roadmap: Glucose sensors |
3.2.2. | Continuous glucose monitors (CGMs) take the form of skin patches |
3.2.3. | CGMs are superseding test strips |
3.2.4. | CGM reimbursement for type 2 is currently limited |
3.2.5. | CGM usage in hospitals |
3.2.6. | Anatomy of a typical CGM device |
3.2.7. | CGM: Technology |
3.2.8. | CGM sensor manufacturing and anatomy |
3.2.9. | Comparison metrics for CGM devices |
3.2.10. | Example: Accuracy of CGM devices over time |
3.2.11. | CGM: Overview of key players |
3.2.12. | Abbott Laboratories: CGM business |
3.2.13. | Dexcom: Introduction |
3.2.14. | Medtronic: Introduction |
3.2.15. | Ascensia, POCTech and Yuwell |
3.2.16. | Senseonics |
3.2.17. | Non-invasive glucose monitoring |
3.2.18. | Conclusions for continuous glucose monitors |
3.2.19. | Insulin pumps |
3.2.20. | Insulin delivery: Introduction |
3.2.21. | Diabetes management device roadmap: Insulin delivery |
3.3. | Insulin Pumps |
3.3.1. | Insulin patch pumps |
3.3.2. | Insulin pump market |
3.3.3. | Insulin pump players and market share |
3.3.4. | Key trends for the industry |
3.3.5. | Accu-Chek Solo by Roche |
3.3.6. | What do patch pumps offer over infusion pumps? |
3.3.7. | Insulin pump technology roadmap |
3.4. | Linking insulin pumps and CGM: Towards closed loop and the artificial pancreas |
3.4.1. | Today: Hybrid closed loop systems |
3.4.2. | The objective: Closing the feedback loop |
3.4.3. | Medtronic leads development of hybrid closed-loop |
3.4.4. | Insulet: Omnipod 5 |
3.4.5. | Tidepool: Tidepool Loop |
3.4.6. | Outlook for insulin pumps |
3.4.7. | Conclusions for insulin delivery |
4. | CARDIAC RHYTHM MONITORING SKIN PATCHES |
4.1.1. | Cardiovascular disease (CVD) |
4.1.2. | Atrial fibrillation and early detection |
4.1.3. | Biopotential indicator and the electrocardiogram |
4.1.4. | Diagnosis process for atrial fibrillation and other arrhythmias |
4.1.5. | ECG monitor pain points that skin patches solve |
4.1.6. | Cardiac monitoring skin patches: device types |
4.1.7. | Cardiac monitoring device types - skin patches |
4.1.8. | Cardiac rhythm monitoring skin patches: companies and product types |
4.1.9. | Cardiac monitoring players and devices (1) |
4.1.10. | Cardiac monitoring players and devices (2) |
4.1.11. | How many ECG channels does a skin patch need? |
4.1.12. | ECGs use wet electrodes and strong adhesives |
4.1.13. | Dry electrodes may improve longer wear experience |
4.1.14. | ECG skin patches are packaged with support AI |
4.1.15. | Reimbursement codes for wearable cardiac monitors |
4.1.16. | Wearable vs implantable monitoring |
4.1.17. | Phillips (Biotelemetry) |
4.1.18. | iRhythm |
4.1.19. | Boston Scientific (Preventice Solutions) |
4.1.20. | Conclusions for cardiac monitoring skin patches |
4.1.21. | Cardiac rhythm monitoring skin patches: company profiles |
4.2. | Fetal heart rate monitoring |
4.2.1. | Fetal monitoring |
4.2.2. | GE Healthcare (Monica Healthcare) |
4.2.3. | Conclusions for fetal heart rate monitoring |
5. | GENERAL PATIENT MONITORING SKIN PATCHES |
5.1. | General vital sign monitoring |
5.2. | Drivers and requirements for skin patches |
5.3. | Application potential for general purpose devices |
5.4. | Deployment challenges for general monitoring devices |
5.5. | Evolving market dynamics over time |
5.6. | Decentralized clinical trials |
5.7. | General patient monitoring skin patch players |
5.8. | Inpatient monitoring |
5.9. | Going wireless |
5.10. | Shifting to outpatient monitoring |
5.11. | Post-Discharge Monitoring: Reducing Readmissions |
5.12. | Neutropenia, post-chemotherapy vital monitoring |
5.13. | Drawback of remote patient monitoring |
5.14. | BioIntelliSense |
5.15. | Vivalink |
5.16. | VitalConnect |
5.17. | Conclusions for general patient monitoring skin patches |
6. | TEMPERATURE SENSING SKIN PATCHES |
6.1. | Body temperature |
6.2. | Skin patches for temperature sensing |
6.3. | Temperature sensor options |
6.4. | Fever and COVID-19 |
6.5. | Fertility monitoring |
6.6. | Temperature monitor skin patch companies |
6.7. | Blue Spark |
6.8. | Conclusions for temperature monitoring skin patches |
7. | ELECTRICAL STIMULATION WITH SKIN PATCHES |
7.1. | Introduction |
7.2. | Differentiation of electrical stimulation |
7.3. | NMES, EMS, and FES |
7.4. | Application of NMES/EMS |
7.5. | Electrical stimulation parameters |
7.6. | First Kind Medical: gecko |
7.7. | TENS |
7.8. | Percutaneous Electrical Stimulation |
7.9. | Communication with Bioelectronic Implants |
7.10. | Electrical stimulation skin patches: company profiles |
7.11. | Conclusions for electrical stimulation skin patches |
8. | IONTOPHORESIS SKIN PATCHES |
8.1. | Introduction |
8.2. | Iontophoresis for Drug Delivery |
8.3. | Commercial Activity: Iontophoresis for Drug Delivery |
8.4. | Iontophoresis for Drug Delivery: Companies |
8.5. | Reverse Iontophoresis |
8.6. | Nemaura Medical |
8.7. | Conclusions for iontophoresis and reverse iontophoresis skin patches |
9. | SWEAT SENSING SKIN PATCHES |
9.1. | Introduction |
9.2. | Galvanic Skin Response |
9.3. | Chemical Sensing in Sweat |
9.4. | Analytes in Sweat |
9.5. | Sweat Sensing: Companies |
9.6. | Conclusion for sweat sensing |
10. | OTHER ELECTRONIC SKIN PATCH APPLICATIONS |
10.1. | Wound Monitoring |
10.2. | Wound Monitoring: Examples |
10.3. | Wound Treatment: Potential Directions |
10.4. | Motion |
10.5. | Motion: Skin Patches vs Other Form Factors |
10.6. | Motion: Inertial Measurement Units and Concussion Monitoring |
10.7. | Motion: Displacement Sensors |
10.8. | Communication with Implants |
10.9. | Communication with Implants: Proteus Digital Health |
10.10. | Ultrasound: Bladder Volume Sensing |
10.11. | Respiration Sound |
11. | MANUFACTURING ELECTRONIC SKIN PATCHES |
11.1.1. | Electronic skin patch manufacturing value chain |
11.2. | Manufacturing methods |
11.2.1. | Electronic skin patch manufacturing process |
11.2.2. | Higher volumes will encourage transition to R2R manufacturing |
11.2.3. | Offering S2S and R2R production enables different order sizes |
11.2.4. | Increased demand for wearable/medical manufacturing leads to expansion plans |
11.2.5. | Membrane switch manufacturers with screen printing capabilities transition to electronic skin patches |
11.2.6. | Interest in wearable sensing continues to grow but technical challenges remain |
11.2.7. | Development from conventional boxed to flexible hybrid electronics will be challenging |
11.2.8. | GE Research: Manufacturing of disposable wearable vital signs monitoring devices |
11.2.9. | NextFlex: Utilizing electronics in silicone to make more comfortable skin patches |
11.2.10. | Key points: Electronic skin patch manufacturing |
11.3. | Materials |
11.3.1. | 'Full-stack' material portfolios reduce adoption barriers |
11.3.2. | Material requirements for an electronic skin patch |
11.3.3. | Progress in using liquid metal alloys as stretchable inks for wearable electronics |
11.3.4. | New printed electrode materials from Henkel |
11.3.5. | Key points: Materials for electronic skin patches |
12. | MARKET FORECASTS |
12.1.1. | Electronic skin patches global market annual revenue historic data 2010-2022 |
12.1.2. | Electronic skin patches global market annual revenue historic data and forecast 2010-2033 |
12.1.3. | Electronic skin patches global market annual revenue historic data and forecast 2010-2033 - excluding diabetes |
12.2. | Diabetes management skin patch market forecasts |
12.2.1. | Forecast: introduction |
12.2.2. | Forecast method: Company revenue in diabetes management |
12.2.3. | Skin patches for diabetes management: market forecast 2022-2033 |
12.2.4. | CGM: annual revenue forecast 2022-2033 |
12.2.5. | CGM: methodology and assumptions |
12.2.6. | CGM: forecasted uptake by type 2 and prediabetes |
12.2.7. | CGM: Milestones |
12.2.8. | CGMs by population adoption proportion |
12.2.9. | Patch pumps revenue forecast 2023-2033 |
12.3. | Cardiac rhythm monitoring skin patch market forecasts |
12.3.1. | Cardiac rhythm management forecasting methodology |
12.3.2. | Cardiac rhythm management global historic market data 2010-2021 |
12.3.3. | Cardiac rhythm management global market forecast 2021-2033 |
12.3.4. | Cardiac rhythm management global market forecast 2010-2033 |
12.3.5. | Cardiac rhythm management global market forecast 2010-2033 |
12.4. | General patient monitoring skin patch market forecasts |
12.4.1. | Methodology for forecasting general patient monitoring |
12.4.2. | General patient monitoring skin patches global market forecast 2023-2033 |
12.4.3. | General patient monitoring skin patches global market historic data and forecast 2010-2033 |
12.5. | Temperature sensing skin patch market forecasts |
12.5.1. | Temperature sensing skin patches global market forecast 2023-2033 |
12.6. | Electrical stimulation skin patch market forecasts |
12.6.1. | Electrical stimulation skin patches: market data (2010-2020) |
12.6.2. | Electrical stimulation skin patches: market forecast (2021-2033) |
12.6.3. | Electrical stimulation skin patches: market data and forecast (2010-2033) |
12.7. | Iontophoresis skin patch market forecasts |
12.7.1. | Iontophoresis skin patches: market forecast (2021-2033) |
12.7.2. | Iontophoresis skin patches: market data and forecast (2010-2033) |
13. | COMPANY PROFILES |
13.1. | Abbott Diabetes care |
13.2. | Agamatrix |
13.3. | Biobeat |
13.4. | BiointelliSense |
13.5. | Bioness |
13.6. | Bittium |
13.7. | Blue Spark |
13.8. | Boston Scientific (Preventice solutions) |
13.9. | Byteflies |
13.10. | Cardiomo |
13.11. | Cortrium |
13.12. | Dexcom |
13.13. | Diabeloop |
13.14. | Epicore |
13.15. | FirstKind |
13.16. | GlucoRx |
13.17. | Grapheal |
13.18. | HiDow |
13.19. | Hivox Biotek |
13.20. | Infinovo |
13.21. | iRhythm |
13.22. | Isansys |
13.23. | Leaf Healthcare |
13.24. | LifeScience Technology |
13.25. | LifeSignals |
13.26. | Medtronic |
13.27. | Medtrum |
13.28. | Mezoo |
13.29. | Philips |
13.30. | Phillips Biotelemetry |
13.31. | Preventice Solutions |
13.32. | QT Medical |
13.33. | Raiing |
13.34. | Roche |
13.35. | Rooti |
13.36. | Scottcare |
13.37. | Seers technology |
13.38. | Sigknow |
13.39. | Singular Wings Medical |
13.40. | SPR Therapeutics |
13.41. | SteadySense |
13.42. | The surgical company |
13.43. | Tidepool |
13.44. | Triple W |
13.45. | VitalConnect |
13.46. | Vivalink |